-
1
-
-
85015226208
-
Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure
-
1 Felker, G.M., Mentz, R.J., Cole, R.T., et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69 (2017), 1399–1406.
-
(2017)
J Am Coll Cardiol
, vol.69
, pp. 1399-1406
-
-
Felker, G.M.1
Mentz, R.J.2
Cole, R.T.3
-
2
-
-
84953343125
-
Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials
-
2 Felker, G.M., Mentz, R.J., Adams, K.F., et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail 8 (2015), 997–1005.
-
(2015)
Circ Heart Fail
, vol.8
, pp. 997-1005
-
-
Felker, G.M.1
Mentz, R.J.2
Adams, K.F.3
-
3
-
-
2142694387
-
Vasopressin receptor antagonists: will the “vaptans” fulfill their promise?
-
3 Francis, G.S., Tang, W.H., Vasopressin receptor antagonists: will the “vaptans” fulfill their promise?. JAMA 291 (2004), 2017–2018.
-
(2004)
JAMA
, vol.291
, pp. 2017-2018
-
-
Francis, G.S.1
Tang, W.H.2
-
4
-
-
33947713810
-
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
-
4 Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
-
(2007)
JAMA
, vol.297
, pp. 1319-1331
-
-
Konstam, M.A.1
Gheorghiade, M.2
Burnett, J.C.3
-
5
-
-
70349464874
-
Effects of tolvaptan on dyspnoea relief from the EVEREST trials
-
5 Pang, P.S., Konstam, M.A., Krasa, H.B., et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 30 (2009), 2233–2240.
-
(2009)
Eur Heart J
, vol.30
, pp. 2233-2240
-
-
Pang, P.S.1
Konstam, M.A.2
Krasa, H.B.3
-
6
-
-
79960090547
-
Effect of nesiritide in patients with acute decompensated heart failure
-
6 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
-
(2011)
N Engl J Med
, vol.365
, pp. 32-43
-
-
O'Connor, C.M.1
Starling, R.C.2
Hernandez, A.F.3
-
7
-
-
84871986523
-
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
-
7 Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
-
(2013)
Lancet
, vol.381
, pp. 29-39
-
-
Teerlink, J.R.1
Cotter, G.2
Davison, B.A.3
-
8
-
-
77955436904
-
A review of dyspnea in acute heart failure syndromes
-
8 West, R.L., Hernandez, A.F., O'Connor, C.M., Starling, R.C., Califf, R.M., A review of dyspnea in acute heart failure syndromes. Am Heart J 160 (2010), 209–214.
-
(2010)
Am Heart J
, vol.160
, pp. 209-214
-
-
West, R.L.1
Hernandez, A.F.2
O'Connor, C.M.3
Starling, R.C.4
Califf, R.M.5
-
9
-
-
84879785466
-
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF
-
9 Mentz, R.J., Hernandez, A.F., Stebbins, A., et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 15 (2013), 456–464.
-
(2013)
Eur J Heart Fail
, vol.15
, pp. 456-464
-
-
Mentz, R.J.1
Hernandez, A.F.2
Stebbins, A.3
-
10
-
-
79959403043
-
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT study
-
10 Metra, M., O'Connor, C.M., Davison, B.A., et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT study. Eur Heart J 32 (2011), 1519–1534.
-
(2011)
Eur Heart J
, vol.32
, pp. 1519-1534
-
-
Metra, M.1
O'Connor, C.M.2
Davison, B.A.3
|